Arcus Biosciences Inc.
03/23/2026 | Press release | Distributed by Public on 03/23/2026 05:46
Management Change/Compensation (Form 8-K)
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On March 17, 2026, Jennifer Jarrett notified Arcus Biosciences, Inc. (the "Company") of her decision to resign from her position as Chief Operating Officer, effective as of March 30, 2026. Ms. Jarrett's resignation is not the result of any disagreement with the Company regarding its operations, policies or practices.
The Company and Ms. Jarrett entered into a separation agreement pursuant to which Ms. Jarrett will make herself available for periodic advisory services for a period through June 30, 2026. In consideration for such services, the Company agreed to extend the post-termination option exercise period during which she may continue to exercise any vested options to twelve (12) months. The separation agreement also contains a standard release of claims. The foregoing description of the separation agreement does not purport to be complete, and is qualified in its entirety by reference to the final separation agreement, a copy of which will be filed with the Company's next quarterly filing on Form 10-Q.
Arcus Biosciences Inc. published this content on March 23, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on March 23, 2026 at 11:46 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]